By Andrew Silver

SHANGHAI, Nov 12 (Reuters) – Eli Lilly on Thursday became the first company to have a GLP-1 weight-loss pill approved in China, gaining a leg up on Danish rival Novo Nordisk in the world’s second-largest pharmaceutical market.

The pill, orforglipron, will compete for market share in China with Lilly’s own once-weekly GLP-1 weight-loss injection as well as with similar injections from Novo, Pfizer, and local ‌firm Innovent Biologics.

Novo and Lilly believe weight-loss pills could ​attract patients reluctant to use injections. Novo has also submitted an application to sell the oral version of Wegovy in China.

Oral therapies account for about a third of US obesity prescriptions following the rollout of Novo’s Wegovy pill in January this year, according to Novo presentations in September.

China’s ​National Health Commission has said the proportion of overweight or obese people ⁠in the country could reach more than 65% by 2030, up from roughly 50% in 2020.

Annual sales of GLP-1 therapies for weight management in China could reach 30 billion yuan ($4.5 billion) in the next five to seven years, up from an estimated 3 billion yuan to 4 billion yuan at present, Yang Huang, J.P. Morgan’s head of China healthcare research, has forecast.

Lilly did not immediately respond to a request for comment on how it will price orforglipron in China or when it would be available. 

(Reporting by Andrew Silver; additional reporting from Beijing newsroom; Editing by Christian Schmollinger and Edwina Gibbs)